within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BB02_Mercaptopurine;

model Mercaptopurine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.16,
    Cl = 2.3333333333333336e-05,
    adminDuration = 600,
    adminMass = 75 / 1000000,
    adminCount = 1,
    Vd = 0.0009,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.018333333333333333,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Mercaptopurine</td></tr><tr><td>ATC code:</td><td>L01BB02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>75</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.9</td><td>L</td></tr>
    <tr><td>clearance:</td><td>84</td><td>L/h/70kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Mercaptopurine is an antimetabolite and purine analog used primarily in the treatment of acute lymphoblastic leukemia and other hematologic malignancies. It works by inhibiting DNA and RNA synthesis in rapidly dividing cells. Mercaptopurine is still approved and commonly used as part of chemotherapy regimens.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with acute lymphoblastic leukemia under oral administration.</p><h4>References</h4><ol><li><p>Balis, FM, et al., &amp; Bleyer, WA (1998). Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children&#x27;s cancer group and pediatric oncology branch study. <i>Blood</i> 92(10) 3569–3577. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9808549/\">https://pubmed.ncbi.nlm.nih.gov/9808549</a></p></li><li><p>Saiz-Rodríguez, M, et al., &amp; Abad-Santos, F (2019). Influence of thiopurine S-methyltransferase polymorphisms in mercaptopurine pharmacokinetics in healthy volunteers. <i>Basic &amp; clinical pharmacology &amp; toxicology</i> 124(4) 449–455. DOI:<a href=\"https://doi.org/10.1111/bcpt.13153\">10.1111/bcpt.13153</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30346660/\">https://pubmed.ncbi.nlm.nih.gov/30346660</a></p></li><li><p>Arun, B, et al., &amp; Gota, V (2024). Bioequivalence study followed by model-informed dose optimization of a powder for oral suspension of 6-mercaptopurine. <i>Pediatric blood &amp; cancer</i> 71(3) e30813–None. DOI:<a href=\"https://doi.org/10.1002/pbc.30813\">10.1002/pbc.30813</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38110844/\">https://pubmed.ncbi.nlm.nih.gov/38110844</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01BB02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Mercaptopurine;
